Scotiabank analyst Greg Harrison lowered the firm’s price target on Apellis (APLS) to $20 from $28 and keeps a Sector Perform rating on the shares. The company had a weak Q1, with Syfovre revenues in geographic atrophy missing expectations due to underfunding of retinal therapeutics co-pay assistance programs and inventory draw down, the analyst tells investors. The firm is lowering its price target on the stock to reflect its updated expectations for Syfovre sales.

Protect Your Portfolio Against Market Uncertainty

Discover companies with rock-solid fundamentals in  TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty,  delivered straight to your inbox.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on APLS:

Disclaimer & DisclosureReport an Issue

Apellis price target lowered to $47 from $55 at Baird Apellis price target lowered to $26 from $30 at Wells Fargo Optimistic Growth Potential for Apellis Pharmaceuticals Despite Temporary Setbacks Hold Rating on Apellis Pharmaceuticals Amid Revenue Uncertainty and Competitive Pressures Apellis Pharmaceuticals Reports Q1 2025 Financial Results

View Comments